In The Press November 20, 2019

US Launch – Five Litigation Strategies European Biosimilar Developers Should Know (Pharma IQ)

In a byline article for Pharma IQ, Goodwin partner Natasha Daughtrey, who serve in the Intellectual Property Litigation group, share insight on how European developers can successfully launch a biosimilar in the U.S. Read the article here.